KRAS and colorectal carcinoma: The difference in percentage of KRAS exon 2 mutations between CD166 positive and CD166 negative CRC specimens is significant (P < 0.05, chi-square test) whereas whereas the difference of it between CD166 positive and CD166 negative CAD specimens is not significant (P = 0.62, chi-square test).